Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
Michael Ittmanna, Rosemary L. Wieczorek, P Heller, A Dave, John A. Provet, John J. Krolewski
- aDepartment of Pathology, New York Department of Veterans Affairs Medical Center 10010
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Alterations in the p53 gene have been described in a variety of human malignant neoplasms. We have examined 29 stage B prostate carcinomas for alterations in the p53 gene and for amplification of the MDM-2 gene. No evidence of mutations in the conserved exons 5 to 8 was found by polymerase chain reaction single-stranded conformation polymorphism analysis and no accumulation of p53 protein was found by immunohistochemistry. However, loss of heterozygosity at the p53 locus was observed in 11% of information cases. Amplification of the MDM-2 gene was not observed by Southern blot hybridization. In contrast, stage C and D prostate carcinomas showed accumulation of p53 protein in 33 to 66% of cases. We conclude that alterations in p53 function are infrequent in clinically localized prostate cancers but are more common in advanced cancers.
TL;DRIt is concluded that alterations in p53 function are infrequent in clinically localized prostate cancers but are more common in advanced cancers. (Semantic Scholar)